Press Releases

 
Press Releases
  Date Title View
Jan 20, 2015
LEXINGTON, Mass., Jan. 20, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it has entered into a definitive purchase agreement with a leading financial services company to raise approximately ...
PDF
Jan 15, 2015
LEXINGTON, Mass., Jan. 15, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced the closing of its previously announced $7.79 million private placement of common stock and warrants. The private placemen...
PDF
Jan 13, 2015
LEXINGTON, Mass., Jan. 13, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it has entered into a definitive purchase agreement to raise approximately $7.79 million in a private placement of co...
PDF
Jan 5, 2015
LEXINGTON, Mass., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that an Investigational New Drug application (IND) to conduct Phase 2 clinical testing of NS2 for the treatment of Sjö...
PDF
Dec 18, 2014
LEXINGTON, Mass., Dec. 18, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that an Investigational New Drug application (IND) to conduct Phase 2 clinical testing of NS2 for the treatment of noninfe...
PDF
Dec 16, 2014
LEXINGTON, Mass., Dec. 16, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that novel anti-inflammatory data on its lead product candidate, NS2, has been accepted for a late-breaking poster present...
PDF
Dec 4, 2014
LEXINGTON, Mass., Dec. 4, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it will collaborate with the National Organization for Rare Disorders (NORD), a non-profit organization dedicated to h...
PDF
Nov 13, 2014
LEXINGTON, Mass., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present a general corporate overview at the Therapeuti...
PDF
Nov 10, 2014
LEXINGTON, Mass., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced its financial results for the third quarter and nine months ended September 30, 2014. Todd C. Brady, M.D., Ph.D., ...
PDF
Nov 3, 2014
BURLINGTON, Mass., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it will issue its financial results for the third quarter and the year to date period ending September 30, 2014 on Mo...
PDF
Page: FirstPrevious ...
9
NextLast